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Abstract
Background: α-mannosidosis is a rare, autosomal-recessive, lysosomal storage disease caused by a deficient activity
of α-mannosidase. Typical symptoms include intellectual, motor and hearing impairment, facial coarsening, and
musculoskeletal abnormalities. Ocular pathologies reported previously were mainly opacities of the cornea and lens,
strabismus, and ocular motility disorders. However, retinal and optic nerve degeneration have been rarely described.
Methods: We report ocular findings of 32 patients with α-mannosidosis. We particularly concentrated on retinal
abnormalities which we supported by posterior segment examination, fundus photography, and Spectral-Domain
optical coherence tomography (SD-OCT) imaging.
Results: Tapeto-retinal degeneration with bone spicule formations in the peripheral retina or macular changes
were seen in three patients (9.4%) on funduscopy; of these, two with optic nerve atrophy. Eight retinal images
could be obtained by OCT or fundus photography; of these, six showed thinning of the outer retinal layers on OCT.
Overall, optic nerve atrophy was seen in six patients (18.8%); of these, four with partial atrophy. Two patients had
partial optic nerve atrophy with no retinal abnormalities on funduscopy. Cataract was seen in two (6.3%), corneal
haze also in two patients (6.3%). Six patients (18.8%) had manifest strabismus, four (12.5%) nystagmus, and in five
patients (15.6%) impaired smooth pursuit eye movements were seen.
Conclusion: Ocular pathologies are not exclusively confined to opacities of the cornea and lens or strabismus and
ocular motility disorders but tapeto-retinal degeneration and optic nerve atrophy may be a common feature in
α-mannosidosis. OCT technology helps detecting early outer retinal thinning which can progress with age and
potentially leads to vision loss over time.
Keywords: α-mannosidosis, Retinal degeneration, Optic nerve atrophy, Ocular findings, OCT
Background
α-mannosidosis is a rare, autosomal-recessive, lysosomal
storage disease arising from a deficiency in lysosomal
α-mannosidase caused by mutations in MAN2B1 located
on chromosome 19 with an estimated prevalence of 0.5–
1:500.000. Deficiency of α-mannosidase leads to accumu-
lation of mannose-rich oligosaccharides in all tissues
resulting in cell dysfunction. Clinical characteristics show
different phenotypic variations including cognitive disabil-
ity with gradual impairment of speech and mental func-
tions, psychosis, motor function and hearing disturbances,
facial and skeletal abnormalities, and immune deficiency.
Two α-mannosidosis phenotypes have been described
based on clinical severity: a severe infantile form (type I)
characterized by early death due to rapid progressive cen-
tral nervous system involvement and a milder phenotype
with a slower disease progression and survival into adult-
hood (type II) [1, 2]. Diagnosis of α-mannosidosis is made
by measuring acid α-mannosidase activity in leukocytes or
other nucleated cells and can be confirmed by genetic
testing. Elevated urinary secretion of mannose-rich oligo-
saccharides is suggestive of the disease, however not diag-
nostic [1]. Öckerman first described a Hurler-like
appearance of a four-year-old boy in 1967. In a postmortal
examination, a large amount of oligosaccharides, espe-
cially mannose-rich oligosaccharides, was found in his or-
gans and tissues [3]. He therefore named the disorder
“mannosidosis” [4]. As it is a deficiency in lysosomal
α-mannosidase, oligosaccharides accumulate in different
* Correspondence: juliane.matlach@unimedizin-mainz.de
1Department of Ophthalmology, University Medical Center, Johannes
Gutenberg University Mainz, Mainz, Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Matlach et al. Orphanet Journal of Rare Diseases  (2018) 13:88 
https://doi.org/10.1186/s13023-018-0829-z
tissues and organs. Since these early clinical descriptions of
mannosidosis, many research groups have contributed to
the characterization of the presenting phenotype, enzyme
and corresponding genes in several species including ocular
pathologies in 20 α-mannosidosis patients [5–8]. Early re-
ports have described strabismus, opacities of the cornea
and lens as typical ocular symptoms and pathologies in
mannosidosis [5]. However, only recently, retinal abnormal-
ities and optic nerve atrophy have been described in a few
case reports and confirmed by electrophysiology or optical
coherence tomography (OCT) as fundus biomicroscopy
only reveals subtle retinal changes [9, 10]. Currently, there
are two treatment options for α-mannosidosis: stem cell
transplantation and enzyme replacement therapy (ERT).
Haematopoietic stem cell transplantation has been reported
in less than 20 patients with different outcomes and a high
risk of morbidity and mortality [11]. The efficacy and safety
of ERT with a recombinant human α-mannosidase (velma-
nase alfa) has been studied in randomized clinical trials [12]
and let to approval by the European Medicines Agency
(EMA) in January 2018.
Here, we report ocular findings of 32 patients including
a report of two siblings with confirmed α-mannosidosis
and especially concentrated on retinal degeneration which
we supported by posterior segment examination, fundus
photography and Spectral-Domain OCT (SD-OCT).
Methods
In total, 32 patients with α-mannosidosis were examined; of
these 25 participated in a multicenter, multinational pro-
spective natural history study of α-mannosidosis (Trial-ID:
rhLAMAN-01). Clinical evaluations included physical
examination, recording of medical history, measurement of
endurance by six-minute walk test and three-minute stair
climb-test, lung function testing, hearing test, echocardiog-
raphy and electrocardiography, and laboratory testing. These
results were previously published by Beck et al. [13]. In this
report, general ophthalmic investigations such as vision,
anterior and posterior segment abnormalities were only
briefly described. These 25 patients were initially examined
between 2007 and 2009 and followed-up over two to three
years. In addition to this, we examined seven more patients
with α-mannosidosis between 2008 and 2017.
In total, seven patients received ERT with velmanase
alfa; of these, six (Man-1, Man-3, Man-4, Man-21,
Man-28, Man-31) began treatment during or before our
ophthalmic examinations; only Man-32 received his treat-
ment after examination (Tables 1 and 2).
Ophthalmological assessment
Ophthalmic examinations were carried out at the
Department of Ophthalmology, University Medical Center
Mainz, Germany.
All patients or their relatives were asked for ocular
history and medication, and underwent a standard
ophthalmic examination including best-corrected vis-
ual acuity (BCVA) testing, slit-lamp biomicroscopy for
anterior segment and indirect ophthalmoscopy for
fundus examination, and assessment of strabismus,
ocular motility and nystagmus. Measurement of the
optic nerve head, peripapillary retinal nerve fiber layer
and macular region using SD-OCT (Spectralis OCT,
Heidelberg Engineering GmbH, Heidelberg, Germany)
was introduced later as part of our examinations and
was therefore only performed in eight of 32 patients.
Due to individual patient’s abilities, not all of the
mentioned examinations could be performed. Some of
these proved to be difficult due to the patients‘ men-
tal and physical disabilities, especially examinations
which need patients’ cooperation (e.g. vision and mo-
tility testing, photographs, OCT). No visual acuity
could be obtained from two patients, one with severe
optic nerve atrophy and retinal degeneration. Ocular
examinations of four patients were proved to be very
difficult to impossible. Our analyses are mainly de-
scriptive and report single cases supported by fundus
photographs and retinal imaging by SD-OCT.
Table 1 Demographics and ocular findings of all patients
n of patients 32
Sex, male/female 19 (59.4%)/13 (40.6%)
Age, years
1st presentation 18.4 ± 11.8 (1–53)
Last presentation 20.8 ± 11.6 (3–53)
BCVA, decimal
1st presentation 0.56 ± 0.28 (0.04–1.00)
Last presentation 0.60 ± 0.25 (0.10–1.00)
ERT with velmanase alfa 7 (21.9%)
Ocular pathologiesa
Lens opacity 3 (9.4%)
Corneal haze 2 (6.3%)
Optic nerve atrophy, also partial 6 (18.8%)
Tapeto-retinal degeneration (by funduscopy) 3 (9.4%)
Tapeto-retinal degeneration (by OCT) 6/8b
Tapeto-retinal degeneration (by photo) 3/8b
Manifest strabismus 6 (18.8%)
Nystagmus 4 (12.5%)
Saccadic/hypometric eye movements 5 (15.6%)
Data are absolute vales (%), mean ± standard deviation (min-max),
as appropriate.
aocular pathologies that were noticed at all presentations
b8 retinal images could be obtained by OCT/fundus photography; of these, 6
showed retinal degeneration on OCT (thinning of the outer layers); in 1
woman, macular edema was seen due to tapeto-retinal degeneration.
Abbreviations: n number of patients, BCVA best-corrected visual acuity, ERT
enzyme replacement therapy, OCT optical coherence tomography
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Results
A total of 32 patients with α-mannosidosis were in-
cluded and ophthalmlogically examined. All patients
were assigned to the attenuated form of α-mannosidosis
(type II). Table 1 summarizes the patients’ demographics
and ocular abnormalities. Some patients were only seen
once whereas others were followed-up over many years.
Mean BCVA at first presentation was 20/40 (decimal
0.56 ± 0.28) with a range between 20/500 (decimal 0.04)
and 20/20 (decimal 1.00); BCVA at the last (available)
presentation was 20/32 (decimal 0.60 ± 0.25) with a
range between 20/200 (decimal 0.10) and 20/20 (decimal
1.00). Cataract was seen in two (6.3%) and corneal haze
also in two patients (6.3%). Manifest strabismus was
seen in six (18.8%), nystagmus in four (12.5%) and im-
paired smooth pursuit or hypometric saccades in five pa-
tients (15.6%) at the first presentation or during
follow-up.
Fundus abnormalities and OCT findings
We have seen retinal changes on funduscopy in some
patients during the course of our examinations over
years; however, it was only until later that we performed
SD-OCT and noticed early changes of the outer retinal
layers. We could bring back and examine four patients
from the natural history study again and found thinning
of outer retinal layers outside the fovea on OCT in all
four patients. Of the seven additional patients that were
included after the natural history study, an OCT was ob-
tained in four; of these two had retinal degeneration of
the outer layers.
Overall, optic nerve atrophy was seen in six patients
(18.8%); of these four with partial atrophy. Tapeto-retinal
degeneration with bone spicule formations in the per-
ipheral retina or macular changes were seen in three pa-
tients (9.4%) on funduscopy (Fig. 1); of these, two with
optic nerve atrophy. Two patients had partial optic
nerve atrophy with no retinal abnormalities on fundus-
copy. However, the other two patients with partial atro-
phy only showed thinning of the outer retinal layers on
OCT that was not seen on funduscopy.
Table 2 shows the genotype and ocular characteristics
of all patients in detail.
Report of two siblings
Case 1
Case 1 is a girl who was diagnosed at the age of two and
a half as having α-mannosidosis due to motor develop-
ment delay and thoracolumbar kyphosis. At the age of
15 she presented with coarse facial features, severe hear-
ing impairment, intellectual disability, ataxia, mitral
valve insufficiency grade I, and recurrent infections. Her
BCVA at the age of 15 was 0.63 (20/32) in both eyes
without evidence of an afferent pupillary defect, an
intraocular pressure reading of 15 mmHg in both eyes
and an unremarkable anterior segment without corneal
haze or cataract. Fundus examination revealed a normal
optic nerve head; the posterior pole was unremarkable
with a normal foveal reflex before the start of ERT.
At the age of 22, weekly treatment of velmanase alfa
was initiated. SD-OCT showed retinal thinning, espe-
cially with loss of the outer retinal layers, atrophy of
the RPE outside the fovea at the age of 24. Within a
year at the age of 25 she developed cystic macular edema
seen on SD-OCT with a reduced vision of 0.25 (20/80);
the posterior pole demonstrated a partial optic nerve atro-
phy and mottled nummular yellow to white deposits at
the level of the RPE, most notable surrounding the optic
nerve head (Fig. 2).
Case 2
Her brother was diagnosed with α-mannosidosis just
after birth. Hearing impairment and motor development
delay were the first recognized symptoms. At the age of
12 he presented with various abnormalities including
coarse facial features, intellectual disability, ataxia, thora-
columbar kyphosis, aortic valve insufficiency grade I,
and recurrent infections. His BCVA was 0.63 (20/32) in
both eyes with a normal pupillary reaction on his first
examination at the age of 12. Before the start of ERT, an-
terior and posterior segment appeared unremarkable
without corneal haze or cataract, optic nerve atrophy or
retinal degeneration. Weekly treatment of velmanase alfa
was started at the age of 15. During follow-up at the age
of 21, SD-OCT demonstrated early outer retinal thin-
ning without any evidence of yellow-white or pigmented
deposits, besides a more visible choroid around the optic
Fig. 1 Tapeto-retinal degeneration in α-mannosidosis. Fundus
photograph of a 33-year-old man with Retinitis Pigmentosa-like
changes in both eyes. Peripheral pigment clumping (green arrows),
partial optic nerve atrophy (blue arrow), chorioretinal atrophy around
the optic disc (black stars), thin retinal vessels (white crosses), and
mottled patches in the macula (yellow circle) were seen
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nerve head and early partial optic nerve atrophy on fun-
duscopy and fundus photography (Fig. 3).
Discussion
We report ocular abnormalities in a large patient popula-
tion of 32 patients with α-mannosidosis. In this to date lar-
gest case series investigating ocular manifestations of
α-mannosidosis patients we detected a high incidence of
retinal degeneration and optic nerve atrophy. Obvious
tapeto-retinal characteristics of the retina as detected by
funduscopy were rarely found; however early thinning of
the outer retina seen on SD-OCT may suggest a progres-
sive nature of this retinal degeneration in α-mannosidosis.
Optic nerve atrophy can be associated with retinal degener-
ation but we have also seen it in some of our patients with-
out any retinal abnormalities. Also of importance is our
observation that four of seven patients treated with
velmanase alfa developed retinal degeneration despite ERT.
Corneal and lenticular opacities as well as strabismus and
motility disorders were less frequent in our cohort of
α-mannosidosis patients and may be a nonspecific finding
as encountered in other storage diseases.
Bennet and co-workers reported on ocular pathologies in
two unrelated patients diagnosed with mannosidosis. One
had type I mannosidosis affected from early childhood with
poor vision, esotropia and cataracts in both eyes. The other
was diagnosed with type II mannosidosis in late adulthood
and maintained normal vision but deteriorated with pro-
gressive neurologic systems and horizontal nystagmus on
lateral gaze [6]. In a report by Arbisser et al. three patients
with α-mannosidosis showed similar lenticular opacities
without any corneal haze. Ophthalmoscopic anomalies
were noticed in two younger patients despite normal elec-
trophysiology. [5]. Histological studies of the eye in humans
with α-mannosidosis are not available; however Jolly et al.
studied this in a bovine model and found vacuoles in differ-
ent cell types including corneal epithelium, Descemet’s
membrane, corneal endothelium, corneal fibroblasts, pig-
mented cells, lens epithelium, lens fibers, pigment epithe-
lium and also all cell types of the neuroretina. Histological
examinations showed that the mannose-rich oligosaccha-
rides were stored in vacuoles. They hypothesized that this
may be the cause of lens and corneal opacities in humans
with α-mannosidosis [7]. Moreover, the retained storage
material in the retina can lead to photoreceptor loss and
Fig. 2 Tapeto-retinal degeneration in α-mannosidosis in two siblings. Fundus photographs (a, b) of the sister revealed progression of retinal
pigment epithelium (RPE) atrophy outside the macula with yellow-white deposits around the optic disc and chorioretinal atrophy (black stars,
b), and partial optic nerve atrophy (blue arrow, b). Optical coherence tomography (OCT) showed perifoveal thinning of the outer retinal layers
and RPE (red arrows, c) with normal retinal layers in the fovea (green bracket, c). A progression of the outer retina thinning was seen and a
cystic macula edema has developed within a year’s time at the age of 25 (red arrows, d)
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tapeto-retinal degeneration [10]. This may also be an ex-
planation for the progression of clinical symptoms includ-
ing retinal degeneration and optic nerve atrophy with age
as we have seen in the two siblings during follow-up. In
contrast to previously published articles on ocular patholo-
gies in α-mannosidosis that mainly concentrated on opaci-
ties of the cornea or lens, strabismus, nystagmus and other
motility disorders, Springer and co-workers described
late-onset retinal dystrophy characterized by decreasing vis-
ual acuity and diminished Ganzfeld electroretinograms in
two brothers with type II α-mannosidosis [9]. Both were in
their thirties when they were first examined. They had
decreasing vision despite normal findings on fundus
examination. Electroretinography showed borderline
scotopic and photopic responses; however clinical examin-
ation was challenging due to the patients’ reduced mental
capacity and inability to cooperate [9]. More recently,
Courtney and Pennesi published a short report of two cases
of retinal dystrophy in α-mannosidosis [10]. This case re-
port is the first to describe, in addition to corneal and len-
ticular opacity, chorioretinal atrophy with retinal thinning,
loss of the outer retina and RPE as well as granular areas of
hyper- and hypoautofluorescence in the macula and sur-
rounding the optic nerve using OCT, fundus autofluores-
cence and fundus photography [10].
Interestingly, certain similar ocular abnormalities can
be found in other storage diseases. In mucopolyasac-
charidoses (MPS), glycosaminoglycans accumulate in the
retina and induce retinal degeneration, pigmentary retin-
opathy with bony spicules, or depigmented chorioretino-
pathy similar to our findings in α-mannosidosis [14–16].
In a recent report by Seok et al. four patients with differ-
ent types of MPS showed retinal degeneration with peri-
foveal thinning of the outer retinal layers on SD-OCT
often despite normal fundus morphology [15]. This is
also in line with our findings that SD-OCT displays early
degeneration of the retina with no or subtle retina
changes on funduscopy.
Another interesting finding of our study is that ERT
with velmanase alfa did not protect some of our patients
receiving ERT during the observational period from de-
veloping retinal degeneration. A phase I-II study evalu-
ated the efficacy and safety of the recombinant human
α-mannosidase (velmanase alfa) in 10 patients with
weekly therapy over 12 months. Borgwardt et al. showed
promising results with improved motor and cognitive
function and reduced oligosaccharide concentrations in
the serum, urine and cerebrospinal fluid [12]. Ocular
changes were not evaluated in this study. In our patients
on long-term ERT, only those starting treatment after
Fig. 3 Tapeto-retinal degeneration in α-mannosidosis in two siblings. Fundus photographs (a, b) of the brother showed early partial optic nerve
atrophy (blue arrow, b) but without any yellow-white or pigmented deposits, besides a more visible choroid around the optic nerve head (black
stars, b). Optical coherence tomography (OCT) showed a perifoveal thinning of the outer retinal layers and retinal pigment epithelium (RPE, red
arrows, c, d) with normal retinal layers in the fovea (green bracket, c, d). However, outer retina thinning progressed over time (smaller green
bracket, d) with a larger perifoveal area of outer retinal atrophy (red arrows, d)
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the age of 14 years developed progressive retinal degener-
ation. One patient starting treatment at the age of 7 years
did not yet develop retinal or optic nerve degeneration.
Theoretically, the efficacy of ERT might be better the youn-
ger the patients are when starting treatment. However, we
cannot conclude yet that ERT might prevent ophthalmo-
logical changes in patients with α-mannosidosis even on
long-term ERT.
Conclusions
In conclusion, ocular pathologies in α-mannosidosis do
not confine to corneal or lenticular opacities. Our investi-
gations revealed retinal and optic nerve degeneration as
common eye pathologies in α-mannosidosis. This is in
contrast to some of the earlier reports of ophthalmological
findings in α-mannosidosis with no clinical significance to
the patients. OCT provides early diagnosis of retinal de-
generation by showing thinning of the outer retinal layers
when conventional funduscopy or photography fails to de-
tect it. Also optic nerve atrophy may be a new feature of
α-mannosidosis. Future larger prospective studies with
retinal imaging such as OCT are required to evaluate inci-
dence of retinal degeneration in α-mannosidosis as it may
be commonly seen when systematically examined with
OCT. Furthermore it has to be investigated whether and
when retinal degeneration progresses in α-mannosidosis
to a potentially vision-threatening ocular disease and how
therapeutic principles such as ERT may influence retinal
degeneration.
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